Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIVE study of irinotecan liposome + capecitabine + bevacizumab in elderly metastatic colorectal cancer after oxaliplatin failure
ChiCTR2500100308Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome, capecitabine and bevacizumab in colorectal cancer (CRC), sponsored by Huashan Hospital. Primary endpoint: Objective response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
irinotecan liposomecapecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500100308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100308.